Liposomal Sustained-Release Delivary Systems for Instravenous Injection. V. : Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-D-Arabinofuranosylcytosine
スポンサーリンク
概要
- 論文の詳細を見る
A lipophilic prodrug of 1-β-D-arabinofuranosylcytosine (Ara-C), N^4-[N-(cholesteryloxy-carbonyl)glycyl]-Ara-C (COCG-Ara-C) was entrapped in unilamellar liposomes or solubilized in pH 7.4 phosphate-buffered saline with hydrogenated castor oil polyethylene glycol ether (HCO-60), and its biological disposition was studied in mice. Regardless of dosage form, COCG-Ara-C was accumulated in the liver after intravenous (i.v.) injection, but not in the lung or kidney. In contrast, the blood clearance and spleen distribution of COCG-Ara-C varied with dosage form : slow blood clearance and increased spleen levels of the prodrug were observed for the liposome-entrapped form relative to the detergent-solubilized form. Both COCG-Ara-C preparations successfully maintained the plasma levels of Ara-C compared with Ara-C aqueous solution. However, the plasma Ara-C concentration-time profiles were markedly different between the preparations. After i.v. injection of liposome-entrapped COCG-Ara-Cm plasma Ara-C levels increased slowly for the first 16 h and subsequently decreased gradually. On the other hand, rapid apperance of Ara-C in the circulation and subsequently gradual elimnation were observed after injection of the detergent-solubilized prodrug. The relative bioavailabilities obtained with respect to Ara-C aqueous solution were 592% and 129% for the liposome-entrapped and detergent-solubilized forms, respectively. The extremely high bioavailability of liposome-entrapped COCG-Ara-C could be explained in part by the finding that the liposome-entrapped prodrug reduced the plasma clearance of the parent drug Ara-C. These results indicate the potential utility of COCG-Ara-C-bearing liposomes as a sustained-release delivery system of Ara-C applied by i.v. injection.
- 社団法人日本薬学会の論文
- 1988-10-25
著者
-
藤崎 二朗
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
-
藤崎 二郎
藤沢薬品工業探索研究所
-
藤崎 二郎
藤沢薬品工業
-
徳永 雄二
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
岩佐 知明
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
沢居 清治
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
加賀山 彰
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
徳永 雄二
Pharmaceutical Institute, Tohoku University
-
徳永 雄二
藤沢薬品工業 開発第二研
-
沢居 清治
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
-
加賀山 彰
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
-
岩佐 知明
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
関連論文
- Regional Capacities of Gastrointestinal Absorption and Lymphatic Transport for Lipid-Soluble Dyes in Rats
- Potential Absorption of Heparin from the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles
- キット製剤の将来展望(E・薬剤学, 製剤学, 病院薬学)
- Liposomal Sustained-Release Delivary Systems for Instravenous Injection. V. : Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-D-Arabinofuranosylcytosine
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. : Antitumor Activity of Newly Synthesized Lipophilic 1-β-D-Arabinofuranosylcytosine Prodrug-Bearing Liposomes
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. III. : Antitumor Activity of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. II. : Design of Liposome Carriers and Blood Disposition of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. I. : Physicochemical and Biological Properties of Newly Synthesized Lipophilic Derivatives of Mitomycin C
- INDIRECT ELECTROREDUCTIVE CYCLIZATION FOR SYNTHESES OF KEY INTERMEDIATES OF SEVERAL INDOLE AND IPECAC ALKALOIDS
- Effect of Some Ionic and Nonionic Surfactants on the Intramuscular Absorption of Isonicotinamide
- O-66 セファメジンαノンバイアルキットの製剤設計 (2) : 製剤特性と機能性評価
- O-65 セファメジンαノンバイアルキットの製剤設計 (1) : 設計コンセプトと有用性評価
- 放出開始時間制御型経口投与システム (TES) の設計
- Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane
- セファメジンαノンバイアルキットの容器設計と品質保証
- Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). II. Design of Multiparticulate TES and in Vitro Drug Release Properties
- Biopharmaceutical Study of the Hepato-biliary Transport of Drugs. IV. Development of the Method to Investigate the Process of the Active Secretion of Drugs from the Hepatocytes into the Bile Canaliculi and Its Application to the Biliary Excretion of Organ